Celldex Therapeutics Inc. (CLDX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Celldex Therapeutics Inc.

    NASDAQ: CLDX · Real-Time Price · USD
    22.78
    -0.83 (-3.52%)
    At close: Sep 04, 2025, 3:59 PM
    22.78
    0.00%
    After-hours: Sep 04, 2025, 05:59 PM EDT

    Celldex Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 7.02M 6.88M 2.36M 4.65M
    Cost of Revenue
    		 3.18M 3.01M 1.4M 3.07M
    Gross Profit
    		 7.02M -111.13M -79.9M 1.58M
    Operating Income
    		 -195.08M -154.54M -115.23M -71.24M
    Interest Income
    		 37.22M 13.11M 2.91M 505K
    Pretax Income
    		 -157.86M -141.43M -112.33M -70.74M
    Net Income
    		 -157.86M -141.43M -112.33M -70.51M
    Selling & General & Admin
    		 38.55M 30.91M 27.2M 20.49M
    Research & Development
    		 163.55M 118.01M 82.26M 50.24M
    Other Expenses
    		 n/a -105.51M -74.12M -48.15M
    Operating Expenses
    		 202.1M 43.41M 35.33M 22.58M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 202.1M 161.43M 117.59M 75.89M
    Income Tax Expense
    		 n/a n/a n/a -227K
    Shares Outstanding (Basic)
    		 64.39M 48.45M 46.89M 42.87M
    Shares Outstanding (Diluted)
    		 64.39M 48.45M 46.89M 42.87M
    EPS (Basic)
    		 -2.45 -2.92 -2.4 -1.64
    EPS (Diluted)
    		 -2.45 -2.92 -2.4 -1.64
    EBITDA
    		 -191.9M -139.03M -104.2M -66.08M
    EBIT
    		 -195.08M -142.04M -107.1M -69.15M
    Depreciation & Amortization
    		 3.18M 3.01M 2.9M 3.07M

    Add to Watchlist